Earlier this month, Cievert was selected by Amgen to address a challenge they set out: “Encourage continuity in treatment strategy and treatment optimization for post-myocardial infarction patients”. Penguin was pitched as the ideal solution for monitoring patients and stratifying risk using data science.
The programme was organised by EIT (European Institute of Innovation and Technology) and brings together Amgen, Bayer, Beiersdorf, Pfizer, and Boehringer Ingelheim. Cievert will be travelling to Germany, Switzerland and Austria to meet the pharmaceutical companies later this year.
Cievert was the only company selected from the UK.
You can read more here.
